Saturday, September 23, 2017

Transcription

1 8 th International Forum for RA Program 12:30 13:00 14:00 Registration open Lunch Saturday, September 23, :00 14:15 Welcome and introduction to the history of and purpose of IFRA Lars Klareskog, Zhanguo Li, Kazuhiko Yamamoto JIM Welcome address Anders Ekbom, Professor KI, Member of the editorial board of Journal of Internal Medicine Session 1: The good aspects of the situation today and how we arrived here Chairs: Zhanguo Li, Kazuhiko Yamamoto 14:15 14:45 From ideas in research to clinical benefits. The long term perspectives Sir Ravinder Maini, Kennedy Institute, University of Oxford Session 2: The unresolved clinical and scientific problems of today and why are they unresolved? Chairs: Tore Kvien, Oslo University and Alison Kent, PARE/EULAR 14:50 15:15 15:15 15:40 Patients needs and current scientific approaches to RA; Not always aligned. Johan Askling, Karolinska Institutet, Stockholm Unresolved problems as seen from the clinician s perspective Merete Hetland, Copenhagen University 15:40 16:05 Scientific unresolved problems in science Chris Buckley, University of Birmingham 16:05 16:30 Discussions on need for novel solutions to adess the most important unresolved questions Discussion led by chairpersons 16: Afternoon break with tea and coffee Session 3: Why do we get RA (1st part); What can we learn from genetic epidemiology and genomics? Chairs: Mike Brenner, Harvard Medical School and Anne Barton, The University of Manchester 17:00 17:25 Polygenic burdens on cell specific pathways underlie the risk of rheumatoid arthritis Kazuhiko Yamamoto, University of Tokyo 17:25 17:50 Rheumatoid arthritis: the role of environment and genes Jill Norris, Denver 17:50 18:15 Combining genetics and epigenetic data to define key pathogenic single cell populations in rheumatoid arthritis Soumya Raychadhuri, Harvard Medical School, Boston, MA

2 18:15 18:30 18:30 19:00 Selected abstract: The association between HLA DRB1 alleles and risk of rheumatoid arthritis is influenced by massive gene gene interactions Lina Marcela Diaz Gallo, Karolinska Institutet, Stockholm Discussions on strategic thinking concerning combinations of cohorts and biomarkers for future design of studies on pathogenesis, prevention and therapy Discussion introduced and led by chairpersons 19:00 21:00 Reception at Aula Medica Sunday, September 24, 2017 Session 4: Why do we get RA? (2nd part) The longitudinal course of RA Chairs: Anna Rudin, Gothenburg University and Mike Holers, University of Colorado at Denver 8:30 8:55 8:55 9:20 9:20 9:45 9:45 10:20 From triggering to targeting; the longitudinal course of seropositive RA Autoantibodies and their glycosylation during emergence of RA ACPAs, NETs and inflammation. New light on neutrophils Anca Catrina, Karolinska Institutet, Stockholm Hans Ulrich Scherer, Leiden University Mariana Kaplan, NIH, Bethesda, MA Pathobiology of Rheumatoid Arthritis: Towards a Molecular Definition and Precision Medicine Cos Pitzalis, London 10:20 10:50 Morning break with coffee and fruits Session 5: Why do we get RA? (3rd part): Microbes and RA Chairs: Rene Toes, Leiden University Medical Center and Solbritt Rantapää Dahlqvist, Umeå University 10:50 11:15 11:15 11:40 The bacterial way towards RA 1: The porphyromonas and PAD pathway Karin Lundberg, Karolinska Institutet, Stockholm The bacterial way towards RA 2: The Aggregatibacter and hypercitrullination way. Felipe Andrade, Johns Hopkins, Baltimore, MD 11:40 12:05 Role of the microbiome in the pathogenesis of RA Xuan Zhang, Peking Union Medical College 12:05 12:30 Discussions on strategies to understand the triggers and early stages of RA Discussion introduced and led by chairpersons from session 4 and 5 12:30 13:30 Lunch

3 Session 6: Adaptive vs. Innate immunity and mesenchymal functions as driving forces in RA Chairs: Andy Cope, King s College London and Steffen Gay, University of Zürich 13:30 13:55 13:55 14:20 14:20 14:45 14:45 15:00 15:00 15:15 15:15 15:45 15:45 16:10 Role of specific B and T cells immunity in RA The B cell repertoire in RA Vivianne Malmström, Karolinska Institutet, Stockholm Dan Mueller, University of Minnesota Effects of monoclonal antibodies from RA patients on innate functions of synovial cells Bill Robinson, Stanford University, CA Selected abstract: Monoclonal ACPA IgG feature extensive Fab glycosylation Katy Lloyd, Karolinska Institutet, Stockholm Selected abstract: The mutated RNA splicing protein hnrnp a3 is a novel autoantigen in systemic rheumatic diseases a link to Warburg effect in RA Bianka Marklein, Charite University, Berlin How can we combine understanding of mesenchymal and immune functions in RA? Iain McInnes, University of Glasgow Discussions on the driving forces of RA Discussion introduced and led by the chairpersons 16:10 16:40 Afternoon break with coffee Session 7: Mechanisms of pain in RA Chairs: Carl Turesson, Lund University and Codruta Filip, PARE/EULAR Pain and cognition in RA, Which are the central mechanisms? 16:40 17:05 Georg Schett, Erlangen University Clinic 17:05 17:30 Longitudinal development of pain in RA Jon Lampa, Karolinska Institutet, Stockholm 17:30 17:55 Antibody mediated pain Camilla Svensson, Karolinska Institutet, Stockholm 17:55 18:15 Discussion introduced and led by the chairpersons 18:15 19:30 Posters with poster competition, discussion clubs and other informal meetings with wine and cheese (posters can be put up during Sunday afternoon and have to be taken down after the end of the poster session.) Speakers dinner

4 Monday, September 25, 2017 Session 8: Adaptive vs innate immunity and mesenchymal functions in RA (continued) Chairs: Lisa van Baarsen, AMC and TBC 8:30 8:55 8:55 9:20 9:20 9:45 9:45 10:00 MFAP5 plays a key role in invasion of FL like synoviocyte in RA Huji Xu, Tsinghua University School of Clinical Medicine, and The Second Military Medical University, China Genetics, T cell specificity and T cell regulation in RA Jane Buckner, Benaroya Research Institute, Seattle, WA How can adaptive immune functions influence stromal cells in RA? Caroline Ospelt, University of Zürich Selected abstract: Machine learning using rheumiatoid arthritis synovial gene expression data defines histologic features that correlate with systemic inflammation and autoantibodies Dana Orange, Rockefeller University 10:00 10:20 Discussions introduced and led by the chairpersons 10:20 10:45 Morning break with coffee Session 9: Genetics and function of citrullination and PAD and other post translational modifications in RA Chairs: Caroline Grönwall, Karolinska Institutet and Ger Pruijn, Radboud University 10:45 11:00 Introduction to post translational modifications Ger Pruijn, Radboud University, Nijmegen 11:00 11:25 The roles of PADs in RA Hirofumi Shoda, University of Tokyo 11:25 11:50 11:50 12:05 Role of osteoclasts in bone inflammation Hiroshi Takayanagi, University of Tokyo Selected abstract: RA associated antibodies targeting post translational modification have different osteoclastogenesis potential Akilan Krishnamurthy, Karolinska Institutet, Stockholm 12:05 12:30 Discussions introduced and led by the chairpersons 12:30 13:45 Lunch Session 10: Can we prevent RA? Chairs: Chairs: Dimitris Boumpas, Biomedical Research Foundation Academy Of Athens and Lars Alfredsson, KI 13:45 14:10 14:10 14:35 Trials for prevention: How to do it? Modifiable risk factors for RA Tom Huizinga, Leiden University Medical Center Saedis Saevarsdottir, Karolinska Institutet 14:35 15:00 How to understand and measure subjective symptoms that matter for the patient? Karim Raza, University of Birmingham 15:00 15:30 Afternoon break with coffee

5 Session 11: New ways of understanding the individual s most urgent problems and how they change over time; What role for e health Chairs: Gerd Burmester, Charité, Berlin and Inger Gjertsson, University of Gothenburg 15:30 15:55 15:55 16:20 16:20 17:05 Emerging opportunities for digital health research in RA Will Dixon, University of Manchester Meeting the patients early with an app: What options and what obstacles? Sofia Ernestam, Karolinska Institutet What will happen with patient reported outcomes in the future? Tore Kvien, Oslo University 17:05 17:30 Discussion introduced and led by the chairpersons from session 10 and 11 18:30 Leave for City Hall (busses will leave from outside Aula Medica) 19:00 The reception in the City Hall is hosted by the Stockholm County Council and the City of Stockholm Tuesday, September 26, 2017 Session 12: Future trials for prevention and curative treatments; Which strategies? 8:30 8:55 Chairs: Marc Feldmann, University of Oxford and Ronald van Vollenhoven, KI and University of Amsterdam Tolerance therapies will they become real? Ranjeny Thomas, University of Queensland 8:55 9:20 Tolerizing T cells Rikard Holmdahl, Karolinska Institutet 9:20 9:45 Antigen specific immunotherapy: tolerance or immune modulation? David Wraith, University of Birmingham 9:45 10:15 Morning break with coffee 10:15 10:40 New smart trial designs John Isaacs, Newcastle University 10:40 11:00 Bioelectronic Medicine: Technology Targeting Molecular Mechanisms for Therapy Peder Olofsson, Karolinska Institutet

6 Session 13: Future strategies for prevention and treatments of RA a collaboration between academia, industry and health care chairs: Lars Klareskog (KI), Marc Feldmann (University of Oxford) and Ronald van Vollenhoven (KI and University of Amsterdam) 11:00 12:30 Discussion with representatives from academia, industry and health care led by the chairpersons Perspectives from industry, academia and health care; How should we combine our efforts to make the new generation of curative and preventive therapies real? Confirmed guests: Anish Suri, Janssen Aaron Winkler, Pfizer Steven Nadler, BMS 12:30 12:55 Alternations in tonsil microbiota associated with RA Zhanguo Li, Beijing University 13:00 Lunch and Departures Practical Information Posters: Can be put up from Sunday lunch time and shall be taken down Sunday evening after the poster session. Our venue is Aula Medica, Nobels väg 6, Solna (Karolinska Institutet campus) To get here from Arlanda airport: Use a credited taxi company, we would recommend Taxi Stockholm or Taxi Kurir There is also a train service to the central of Stockholm from Arlanda; Arlanda express. Public transport is run by SL, they offer a variety of tickets which all must be bought before entering the train or bus. Plan your travel here: